June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Metabolomic profiling of dogs with ADAMTS10-open-angle glaucoma (ADAMTS10-OAG)
Author Affiliations & Notes
  • Andras M Komaromy
    Veterinary Medicine, Michigan State University, East Lansing, Michigan, United States
  • Christine Harman
    Veterinary Medicine, Michigan State University, East Lansing, Michigan, United States
  • Amanda Anderson
    Veterinary Medicine, Michigan State University, East Lansing, Michigan, United States
  • Pete Williams
    Clinical Neuroscience, Karolinska Institutet, Stockholm, Stockholm, Sweden
  • Footnotes
    Commercial Relationships   Andras Komaromy Reichert Technologies , Code C (Consultant/Contractor), PolyActiva Pty. Ltd., Code F (Financial Support), CRISPR Therapeutics, Code F (Financial Support), Advanced Ophthalmics LLC, Code F (Financial Support); Christine Harman None; Amanda Anderson None; Pete Williams None
  • Footnotes
    Support  NIH grants R01-EY025752 & R01-EY032478, BrightFocus Foundation grant G2022007S, Vetenskapsrådet (2018-02124)
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 3015. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Andras M Komaromy, Christine Harman, Amanda Anderson, Pete Williams; Metabolomic profiling of dogs with ADAMTS10-open-angle glaucoma (ADAMTS10-OAG). Invest. Ophthalmol. Vis. Sci. 2023;64(8):3015.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : No systemic biomarkers for glaucoma can predict progression rates, disease severity, or treatment efficacy. This study aimed to identify systemic (plasma) and local (aqueous humor) biomarkers associated with the G661R missense mutation in the ADAMTS10 gene resulting in open-angle glaucoma (ADAMTS10-OAG) in dogs.

Methods : Plasma and aqueous humor samples were collected from 24 dogs (14 females & 10 males; median age: 3.5 years, range: 0.9-5.4 years): 19 dogs homozygous for the G661R missense mutation in the ADAMTS10 gene at different stages of OAG, and 5 unaffected controls (i.e., wild-type controls and heterozygous carriers of the G661R missense mutation). Samples were processed for targeted metabolomics via UHPLC-QTOF-MS, identifying >230 annotated metabolites. Data were analyzed using MetaboAnalyst 5.0 in R, normalized by Pareto scaling, and statistical enrichment performed (Fisher’s at an FDR of <0.05) to determine differences between groups. Pathway analysis (KEGG) was performed using differentially changed metabolites from the first analysis.

Results : Both aqueous humor and plasma demonstrated distinct metabolic profiles between OAG and control groups. Of the 233 metabolites identified, 32 were differentially expressed in the aqueous humor of ADAMTS10-mutant dogs. In comparison, 21 metabolites were differentially expressed in plasma samples. The following 7 metabolites were differentially expressed in plasma and aqueous humor: N-acetyltryptophan, kynurenic acid, 2-ketobutyric acid, 4-trimethylammoniobutanoic acid, cis-4-decenoylcarnitine, 3-methylhistidine, and gamma-aminobutyric acid. While only one pathway was significantly affected in the mutant plasma – valine, leucine, and isoleucine biosynthesis – the following 7 pathways were altered in the mutant aqueous humor: alanine, aspartate & glutamate, butanoate, citrate cycle, propanoate, glyoxylate and dicarboxylate, and D-glutamine and D-glutamate metabolisms, as well as lysine degradation.

Conclusions : In this initial metabolomic study, changes in metabolites were found in plasma and aqueous humor in a clinically relevant and well-established large animal OAG model. Metabolomics may be a valuable tool to stage diseases and assess response to therapy.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×